The Potential of Soluble Epoxide Hydrolase Inhibition in the Treatment of Cardiac Hypertrophy

Congestive Heart Failure

Volumn 14, Issue 4, 2008, Pages 219-224

  Harris, Todd R ^a   Li, Ning ^b   Chiamvimonvat, Nipavan ^b,c   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXIDE HYDROLASE; RECOMBINANT PROTEIN;

CARDIOMEGALY; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM; HUMAN; REVIEW;

CARDIOMEGALY; ENDOTHELIUM; EPOXIDE HYDROLASES; HUMANS; RECOMBINANT PROTEINS;

EID: 55249086714     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.08430.x     Document Type: Note

References (30)

1. Spector AA, Norris AW. Action of epoxyeicosa-trienoic acids on cellular function. Am J Physiol Cell Physiol.2007;292(3):C996-C1012.
2. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev.2006;24(2):169-188.
3. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A.2006;103(49):18733-18738.
4. Goto K, Fujii K, Kansui Y, et al. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors. Clin Exp Pharmacol Physiol.2004;31(9):650-655.
5. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardio-renal effects and implications for renal and cardiovascular disease states. Am J Med Sci.2003;326(1):15-24.
6. Chiamvimonvat N, Ho CM, Tsai HJ, et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol.2007;50(3):225-237.
7. Inceoglu B, Schmelzer KR, Morisseau C, et al. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosa-trienoic acids (EETs). Prostaglandins Other Lipid Mediat.2007;82(1-4):42-49.
8. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res.2005;44(1):1-51.
9. Morisseau C, Hammock BD. Epoxide hydro-lases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol.2005;45:311-333.
10. Wixtrom RN, Hammock BD. Membrane-bound and soluble fraction epoxide hydro-lases. In: Zakim D, Vessey DA, eds. Biochemical Pharmacology and Toxicology. New York, NY: Wiley; 1985:1-93.
11. Capdevila JH, Falck JR, Estabrook RW. Cytochrome P450 and the arachidonate cascade. FASEB J.1992;6(2):731-736.
12. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-1875.
13. Schwarz D, Kisselev P, Ericksen SS, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective for-mationof17(R),18(S)-epoxyeicosatetraenoicacid. Biochem Pharmacol.2004;67(8):1445-1457.
14. VanRollins M. Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting throm-boxane synthesis. J Pharmacol Exp Ther. 1995;274(2):798-804.
15. Imig JD. Epoxide hydrolase and epoxyge-nase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005;289(3):F496-F503.
16. Frey N, Katus HA, Olson EN, et al. Hypertrophy of the heart: a new therapeutic target? Circulation.2004;109(13):1580-1589.
17. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation.2002;105(1):85-92.
18. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell.1996;87(1):13-20.
19. Karin M. How NF-kB is activated: the role of the IkB kinase (IKK) complex. Oncogene. 1999;18(49):6867-6874.
20. Purcell NH, Molkentin JD. Is nuclear factor kB an attractive therapeutic target for treating cardiac hypertrophy? Circulation. 2003;108(6):638-640.
21. Gupta S, Purcell NH, Lin A, et al. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol.2002;159(6):1019-1028.
22. Hirotani S, Otsu K, Nishida K, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002;105(4):509-515.
23. Craig R, Wagner M, McCardle T, et al. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kB. J Biol Chem. 2001;276(40):37621-37629.
24. Force T, Kuida K, Namchuk M, et al. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation.2004;109(10):1196-1205.
25. Rouet-Benzineb P, Gontero B, Dreyfus P, et al. Angiotensin II induces nuclear factor- kB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol.2000;32(10):1767-1778.
26. Zechner D, Craig R, Hanford DS, et al. MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner. J Biol Chem.1998;273(14):8232-8239.
27. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol. 2007;102(4):279-297.
28. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91(9):776-781.
29. Matsumori A, Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev. 2001;6(2):129-136.
30. Karin M, Lin A. NF-kB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-227.